Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA.

Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.

The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC.

Immobilized CS1/CRACC/SLAMF7, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 2.2 ng/ml determined by ELISA.

The purity of CS1/CRACC/SLAMF7, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

CS1/CRACC/SLAMF7, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

CS1/CRACC/SLAMF7, His & Avi, Human

CD2-like receptor activating cytotoxic cells (CRACC), also known as CS1, novel Ly9, SLAMF7, and CD319, is a 65-75 kDa type I transmembrane glycoprotein in the SLAM subgroup of the CD2 family, a self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune responses.

Cat. No.	Z03649
Size	100 μg : Quote Buy in bulk
Quantity
Price	¥37,309.00


Ask us a question

Product Introduction

Species

Human

Protein Construction

SLAMF7 (Ser23-Met226) Accession # Q9NQ25	Poly-His	Avi
N-term		C-term

Purity

> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC

Endotoxin Level

≤ 1 EU/μg of protein by LAL method

Biological Activity

Measured by its binding ability in a functional ELISA. Immobilized CS1/CRACC/SLAMF7, His & Avi, Human at 1μg/ml (100μl/well) on the plate can bind AntiSLAMF7 Antibody, hFc Tag. Test result was comparable to standard batch.

Expression System

HEK293

Theoretical Molecular Weight

25.3 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 40-55 kDa based on Bis-Tris PAGE result.

Formulation

Lyophilized from a 0.22 μm filtered solution in PBS, pH 7.4.

Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O more than 100 μg/ml.

Storage & Stability

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples

Immobilized SLAMF7, His & Avi tag at 1 ug/ml (100 ul/Well). Dose response curve for Elotuzumab with the EC50 of 42.6 ng/ml determined by ELISA.

Recombinant Human CRACC/SLAMF7 Protein on SDS-PAGE under reducing conditions, the purity is greater than 95%.

The purity of Recombinant Human CRACC/SLAMF7 Protein is greater than 95% as determined by SEC-HPLC.

Immobilized CS1/CRACC/SLAMF7, His & Avi, Human, His Tag at 1 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-SLAMF7 Antibody, hFc Tag with the EC50 of 2.2 ng/ml determined by ELISA.

The purity of CS1/CRACC/SLAMF7, His & Avi, Human is greater than 95% as determined by SEC-HPLC.

CS1/CRACC/SLAMF7, His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

Background

Target Background

Synonyms

CD319 antigen; CD319; 19A; CD2 subset 1; CD2-like receptor activating cytotoxic cells; CRACC; CRACCCD2-like receptor-activating cytotoxic cells; CS119A24 protein; Membrane protein FOAP-12; novel LY9 (lymphocyte antigen 9) like protein; Novel Ly9; Protein 19A; SLAM family member 7; SLAMF7; CS1

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

CS1/CRACC/SLAMF7, His & Avi, Human

サポート

会社情報

サポート

会社情報